Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of Savolitinib Brain Exposure in Healthy Volunteers
NCT06348355Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in non-small cell lung cancer (NSCLC) and papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Primary endpoint: Percentage of injected radioactivity entering the brain. Started Apr 2024; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT06348355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348355.